FMC Corporation

FMC Corporation (FMC) Market Cap

FMC Corporation has a market capitalization of .

No quote data available.

CEO: Pierre R. Brondeau

Sector: Basic Materials

Industry: Agricultural Inputs

IPO Date: 1980-03-17

Website: https://www.fmc.com

FMC Corporation (FMC) - Company Information

Market Cap: -|Sector: Basic Materials

Company Profile

FMC Corporation, an agricultural sciences company, provides crop protection, plant health, and professional pest and turf management products. It develops, markets, and sells crop protection chemicals that include insecticides, herbicides, and fungicides; and biologicals, crop nutrition, and seed treatment products, which are used in agriculture to enhance crop yield and quality by controlling a range of insects, weeds, and diseases, as well as in non-agricultural markets for pest control. The company markets its products through its own sales organization and through alliance partners, independent distributors, and sales representatives. It operates in North America, Latin America, Europe, the Middle East, Africa, and Asia. FMC Corporation was founded in 1883 and is headquartered in Philadelphia, Pennsylvania.

Analyst Sentiment

53%
Hold

From 17 Active Polls

1Y Forecast: $15.58

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$13

Median

$15

High Bound

$20

Average

$16

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$15.58
▲ +33.85% Upside
Low Target
$13.00
12% Risk
Median Target
$14.75
27% Mid
High Target
$20.00
72% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 FMC CORP (FMC) — Investment Overview

🧩 Business Model Overview

FMC primarily operates in two connected but distinct value chains: (1) Agricultural Solutions and (2) Lithium (where present in the portfolio). In Agricultural Solutions, FMC develops and manufactures crop protection products—herbicides, insecticides, and related chemistries—then monetizes them through a global network of distributors, dealers, and direct regional selling. The business is “technical + regulatory” rather than purely transactional: products require regulatory approvals, formulation know-how, and agronomic support to earn farmer adoption across different geographies and crop regimes.

In Lithium, FMC’s model (when applicable to the current portfolio configuration) is a resource-to-chemicals pathway: concentrate/brine sourcing, conversion into battery-relevant intermediates/products, and sales into downstream battery supply chains. The value driver is not only reserves, but also the ability to produce at competitive cash costs and deliver reliably via logistics and contract structures.

💰 Revenue Streams & Monetisation Model

Agricultural Solutions revenue is largely product sales tied to the crop cycle, with partial defensibility coming from repeat use and switching frictions created by field performance and regulatory trail-data. Monetisation typically depends on:

  • Product portfolio mix: higher-margin specialty/need-based products versus more commoditized chemistries.
  • Geographic fit: products tailored to local pest pressures, application windows, and regulatory allowances.
  • Value-chain services: agronomic trials, technical stewardship, and co-development with channel partners that increase adoption stickiness.

Lithium revenue is more volume- and pricing-sensitive, with margin behavior influenced by feedstock economics, energy and conversion costs, and sales terms into battery intermediates. The monetisation profile is therefore tied to cost competitiveness and contract/granularity of customer qualification.

🧠 Competitive Advantages & Market Positioning

FMC’s moat is best characterized as a blend of regulatory/IP barriers and technical know-how that reduces effective switching—especially in crop protection—plus cost and logistics advantages in resource-based lithium operations.

  • Agricultural Solutions — Regulatory and Adoption Barriers (Intangible + “hard to copy”): Competitors cannot easily replicate FMC’s position because pesticide product lifecycles depend on regulatory dossiers, country-by-country registrations, and multi-year performance/efficacy data. Even when active ingredients become available to others, branded performance packages, formulation expertise, and application guidance create friction for customers to switch vendors without risking yield outcomes.
  • Agricultural Solutions — Technical Service as Switching Friction (Practical Switching Costs): Adoption relies on agronomic fit and farmer-level results. This embeds FMC products into local practice patterns, increasing the cost of trial-and-error for new entrants.
  • Lithium — Low-Cost Production Economics + Logistical Infrastructure (Geographic/Operational Cost Advantage): Battery material supply chains require reliable delivery and consistent specs. Resource location, conversion process efficiency, and route-to-market logistics (including terminals and contracted shipping arrangements) determine sustained unit economics.

Competitive benchmarking (crop protection focus):

  • Bayer and Corteva: broad portfolios spanning major platforms and strong global commercialization. Their scale can pressure pricing on commoditized actives.
  • Syngenta (and peers within the crop protection ecosystem): competitive in specialty and regional products with extensive trial programs.

FMC’s positioning versus these rivals: FMC has historically emphasized a specialty-focused strategy—prioritizing products and programs where regulatory status, performance differentiation, and technical stewardship matter—rather than competing head-on across the entire spectrum of large-scale commodity chemistries. This creates a more defensible niche, especially in crops/geographies where formulation fit and regulatory allowances are decisive.

🚀 Multi-Year Growth Drivers

  • Higher-quality crop yield protection demand: adoption of integrated pest management and resistance management favors products that can be used strategically across seasons (including rotation and targeted modes of action).
  • Specialty and differentiated formulations: growth tends to be more durable where chemistry plus application logic produces measurable agronomic outcomes, supporting premium placement within crop protection programs.
  • Regulatory “barrier to replacement” tailwind: once registrations and stewardship programs are established, re-approval and requalification create time and cost disadvantages for new entrants.
  • Lithium ecosystem demand: over a 5–10 year horizon, battery-driven electrification supports structural demand for battery materials, where suppliers that maintain competitive cash costs and reliable delivery can win through qualification and contract cycles.
  • Portfolio optimization: continued emphasis on allocating capital toward products/locations with better long-run returns can improve resilience across commodity and regulatory cycles.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: changes in pesticide approvals, maximum residue limits, or stewardship requirements can disrupt product economics and require reformulation or portfolio shifts.
  • Resistance and efficacy risk: pest adaptation can reduce product performance over time, requiring chemical rotations and new launches to sustain share.
  • Concentration and crop-cycle volatility: purchasing patterns in agriculture remain seasonal and can vary with weather, input economics, and farmer profitability.
  • Litigation and product liability: agrochemical products can face legal and regulatory scrutiny, particularly where usage patterns or environmental data evolve.
  • Capital intensity and execution in lithium (if materially exposed): ramp-up execution, process yields, and sustaining unit economics are key. Logistics and contract terms also affect realized margins.

📊 Valuation & Market View

The market typically values crop protection and specialty chemical businesses using enterprise value versus earnings power (EV/EBITDA), while also watching free cash flow durability given product-cycle cyclicality. For lithium-exposed businesses, valuation sensitivity increases to commodity-driven margin assumptions, production cost curves, and the credibility of volume ramp and customer qualification.

Key drivers that tend to move valuation multiples include:

  • Stability and mix shift toward specialty/differentiated products in Agricultural Solutions.
  • Evidence of registration pipeline and product lifecycle management that reduces cliff-risk.
  • Unit-cost performance and logistics reliability (especially in resource-based operations).
  • Capital allocation discipline that maintains balance sheet flexibility through regulatory and demand cycles.

🔍 Investment Takeaway

FMC’s long-term investment case rests on defensibility in Agricultural Solutions via regulatory/IP barriers and technical switching friction, supported by a specialty-focused portfolio strategy that can outperform commoditized exposure during adverse pricing environments. Where lithium exposure is material, sustained advantage depends on low-cost production economics and delivery/logistics capability into qualified battery customers. The most durable outcomes come from consistent product stewardship, an execution-capable pipeline, and cost discipline that protects cash generation through cyclical and regulatory volatility.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"FMC reported Q1’26 revenue of $758.6M and net income of -$281.3M (EPS: -$2.25). On a YoY basis, revenue declined vs. Q1’25 ($791.4M), down -4.1%, while net income deteriorated materially from -$15.5M to -$281.3M. QoQ, revenue fell sharply from Q4’25 ($1.1365B) to $758.6M (-33.3%), and profitability weakened: net income swung from -$1.7208B in Q4’25 to -$281.3M in Q1’26 (an improvement, but still deeply negative). Over the last four quarters, margins have been unstable—gross margin contracted to 32.5% in Q1’26 from 42.5% in Q4’25, while operating margin remained close to breakeven in Q1’26 (+0.45%) but net margin stayed deeply negative (-37.1%) due to major non-operating costs (income before tax was -19.7%). Cash flow quality deteriorated: operating cash flow was -$600.9M and free cash flow was -$600.9M in Q1’26, with cash dropping to $390.9M from $584.5M. Balance-sheet resilience is mixed: total assets were $9.42B, but liquidity weakened and net debt was elevated (~$1.37B). Shareholder returns appear weak: price is $17.17 with a -53.9% 1-year change and no dividend yield support (~0). Total return is likely dominated by capital depreciation rather than income. Analyst targets remain below the current price (consensus ~$15.58; high $20, low $13), implying limited near-term upside."

Revenue Growth

Neutral

QoQ revenue fell -33.3% (Q4’25 $1.1365B to Q1’26 $758.6M). YoY revenue declined -4.1% (Q1’25 $791.4M to Q1’26 $758.6M).

Profitability

Neutral

Gross margin contracted to 32.5% (from 42.5% in Q4’25). Net income worsened YoY (from -$15.5M to -$281.3M) and remains deeply negative (net margin -37.1%). EPS: -$2.25 vs -$0.12 YoY.

Cash Flow Quality

Neutral

Q1’26 operating cash flow was -$600.9M and free cash flow -$600.9M. Cash declined to $390.9M from $584.5M in Q4’25, indicating weakening cash generation/working-capital dynamics.

Leverage & Balance Sheet

Caution

Total assets were $9.42B; liquidity weakened (cash down QoQ). Debt burden remains meaningful (short-term debt $1.763B; net debt ~ $1.37B). Equity line items appear volatile across quarters.

Shareholder Returns

Neutral

1-year price momentum is strongly negative: -53.9% over 1Y. Dividend yield is ~0, so total shareholder return is likely dominated by capital depreciation; no meaningful buyback signal in cash flow (Q1’26 repurchases: $0).

Analyst Sentiment & Valuation

Fair

Street consensus target (~$15.58) is below the current price ($17.17), suggesting limited upside. However, high target ($20) leaves room if expectations improve.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

FMC delivered Q1 results above guidance midpoint, driven by favorable FX/volume and cost/EBITDA outperformance, but the underlying profile remains pressured by competitive pricing and stressed customer liquidity. The quarter’s sales were $762m (+$12m vs midpoint) with EBITDA $72m ($17m above the high end) and adjusted EPS -$0.23 (better than midpoint by $0.15). Management’s 2026 plan centers on ~$1B debt paydown via India sale (definitive agreement targeted in May) plus asset monetizations and a licensing upfront payment. Operationally, FMC is rebuilding competitiveness through Asia production shifts completed by Q1 2027 and post-patent Rynaxypyr repositioning aimed at flat branded earnings with share gains evidenced early. The key debate in Q&A was confidence in the H2 ramp: management cites Brazil direct-sales order milestones, reduced partner headwinds in H2, and new active ingredients (Isoflex/fluindapyr/Dodhylex) demand doubling YoY. Guidance is maintained amid tariff/Iran uncertainty, assuming offsetting effects.

AI IconGrowth Catalysts

  • Isoflex active regulatory approval in the EU; launches expected to begin in 2027 with access to 55+ million planted hectares
  • Isoflex Italy/Germany/France/Spain preregistration exemptions requested for 2026 upside to H2
  • Fluindapyr: fast growth limited mainly by registration timing; 19 registrations pending to expand direct-sales in Brazil and other markets
  • Dod hylex active growth; new active ingredients (Isoflex, fluindapyr, Dodhylex) sales doubled YoY in Q1
  • Rynaxypyr post-patent repositioning: volume growth in high-load formulations and differentiated mixtures; early evidence of small share gains from other insecticide classes

Business Development

  • India commercial business sale: late-stage with several potential buyers; definitive agreement expected in May
  • Licensing discussions: advanced talks with multiple potential partners for licensing one new active ingredient, expected to include an upfront payment; conclusion expected in coming weeks
  • Strategic alternatives evaluation announced February 2026: multiple options being evaluated; more clarity by end of Q2
  • Partner/diamide arrangements: lower sales to diamide partners driving price decline effects; branded and partner Rynaxypyr dynamics highlighted in Q&A

AI IconFinancial Highlights

  • Q1 sales $762m, $12m above guidance midpoint; driven by favorable FX and volume; 4% YoY lower but +1% like-for-like excluding India
  • Q1 first-quarter crop protection margins pressured by customer/grower liquidity and cautious purchasing; more pronounced competitive pressure in LatAm and Asia
  • Q1 EBITDA $72m; $17m above high end of guidance range due to favorable FX, cost, and volume
  • Adjusted loss per share (EPS) -$0.23, $0.15 better than guidance midpoint due to higher EBITDA
  • Price declines: Q1 average sales down 6% overall; nearly half of that from lower sales to diamide partners
  • Q2 outlook: revenue $850m–$900m; midpoint down 17% YoY largely due to lower diamide partner sales and removal of India; adjusted EBITDA $130m–$150m (down 32% at midpoint YoY); adjusted EPS -$0.16–$0.26
  • Full-year 2026 guidance unchanged: sales $3.6b–$3.8b (midpoint -5% YoY); adjusted EPS $1.63–$1.89 (41% decline at midpoint); EBITDA $670m–$730m
  • Tariff/Iran uncertainty: management assuming Iran-related cost pressure and tariff-related benefits largely offset; guidance unchanged despite higher energy/transport/petrochemical costs flowing into product costs

AI IconCapital Funding

  • Debt reduction target: approximately $1 billion paydown in 2026
  • Cash/debt (Q1 end): gross debt ~$4.5b (+$459m vs year-end); cash on hand $391m (-$194m); net debt ~$4.1b (+$652m vs year-end)
  • Liquidity/credit facility: April 16 revolver amendment effective—now fully secured; capacity $2b; maturity June 2028; substantial over-collateralization noted
  • Covenants: max total leverage covenant reinstated December 31, 2026 at 6.75x through Dec 31, 2027; secured leverage covenant 3.5x trailing 12-month EBITDA
  • Planned capital markets activity: go-to-market quarter for secured high-yield bond offering to redeem $500m notes maturing in October
  • Free cash flow: Q1 negative $628m (worse by $32m YoY); 2026 free cash flow expected -$65m to +$65m/breakeven at midpoint including ~$150m restructuring cash spend

AI IconStrategy & Ops

  • Manufacturing cost optimization: shift production from high-cost plants to lower-cost sources in Asia; transition expected completed by Q1 2027
  • Asia restructuring completed already for reduced post-India business size (ahead of India sale)
  • Rynaxypyr post-patent strategy: drive sales growth while keeping overall branded earnings flat; early signs include price repositioning + volume growth and some small share gains
  • New direct sales organization impact: orders for Brazil direct sales ramping faster than prior year, supported by direct-sales org implemented in 2025 and now fully in action
  • Board evaluating strategic alternatives (announced February 2026) alongside ongoing debt paydown and asset monetizations

AI IconMarket Outlook

  • Q2 2026: revenue $850m–$900m; adjusted EBITDA $130m–$150m; adjusted EPS $0.16–$0.26 (loss-to-profit range, per guidance language)
  • H2 2026 (implied midpoint): sales and EBITDA largely consistent with last year's second half; sales excluding India up ~1% vs last year; EBITDA down 6% at midpoint vs last year; adjusted EPS down 15% due to lower EBITDA plus higher tax and higher interest
  • H2 volume contribution to EBITDA: roughly 2/3 driven by new active ingredients, particularly in LatAm and EMEA
  • Brazil order book milestones: end of April orders represent 32% of H2 direct sales in Brazil; by end of June expected ~half of second-half direct sales

AI IconRisks & Headwinds

  • Competitive pressure driving lower pricing and cautious purchasing: margins stressed; higher willingness to use generics or skip preventative applications (LatAm and Asia called out)
  • Post-patent Rynaxypyr dynamics: customers adopting wait-and-see approach while assessing availability/efficacy of CTPR generic offerings
  • Rynaxypyr partner/diamide headwinds: price declines and lower partner volumes materially affect results (Q2 decline mainly from diamide partner sales and India removal)
  • Tariffs and Iran conflict uncertainty: higher energy/transport/petrochemical costs already flowing through; management assumes offset between Iran-related cost pressure and tariff benefit—magnitude/timing hard to forecast
  • Input cost visibility limited: concerns about raw material price increases and transportation/distribution delays; management did not factor generic price increases into H2 due to timing (not yet reached market)

Q&A: Analyst Interest

  • H2 bridge drivers and biggest challenges: Management attributed the ~$425m midpoint H2 sales improvement to three buckets—non-diamide core ($150m–$200m) led by Brazil direct sales, Rynaxypyr ($50m–$80m) via reduced partner headwind, and new active ingredients ($175m–$200m) supported by demand and cereal season timing.
  • Rynaxypyr partner price/volume mechanics and reconciliation: Management reconciled partner sales dynamics by highlighting that the highest Rynaxypyr price drops were earlier (2025 vs 2024) tied to cost reduction. They forecast 2026 partner sales falling below $100m vs $200m in prior year, while branded remains ~$600m with flat earnings.
  • Input costs, Iran impacts, and whether to factor generics pricing: Management said insufficient visibility exists to size future input-cost impact, noting Iran affects transportation/distribution delays and raw material/energy costs, but if conflict ends soon impact may be minor. For generics, they saw leveling (no spiral down) and did not factor potential price increases yet.

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the FMC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — FMC Corporation (FMC) Financial Profile